Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Like other cancers, melanoma is rising among young adults. It's now the 2nd most common cancer in 15 to 39 year-olds.

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for the treatment of adult patients with resectable locally advanced head and ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...